Table 2.
Multivariate regression model of EDSS < 3 at diagnosis including demographic and severity variables.
| Predictor | Coefficient | Standard error | p-value | 95% confidence interval |
|---|---|---|---|---|
| Gas6 serum (ng/mL) | −0.0169 | 0.0075 | 0.029 | −0.0320–−0.0018 |
| Gas6 CSF (ng/mL) | −0.0192 | 0.0089 | 0.037 | −0.0372–−0.0012 |
| sAXL serum (ng/mL) | −0.0026 | 0.0044 | 0.55 | −0.0112–0.0063 |
| sMer serum (ng/mL) | 0.0067 | 0.0081 | 0.41 | −0.0097–0.0231 |
| sTyro-3 serum (ng/mL) | 0.0002 | 0.0290 | 0.99 | −0.0582–0.0586 |
| NFL serum (pg/mL) | 0.0020 | 0.0011 | 0.21 | −0.0026–0.0044 |
| Age | 0.0025 | 0.0045 | 0.58 | −0.0066–0.0116 |
| Gender | −0.060 | 0.0936 | 0.52 | −0.2487–0.1279 |
| N° brain lesion >10 | 0.1444 | 0.0907 | 0.11 | −0.0381–0.3269 |
| Spinal lesion | 0.0985 | 0.0900 | 0.28 | 0.0819–0.2871 |
| Gadolinium enhancing | 0.7653 | 0.6075 | 0.41 | −0.0826–0.2796 |
In bold are indicated statistically significant results (p < 0.05). After the multivariate analysis, only serum and CSF Gas6 levels (p = 0.029; p = 0.037) resulted as predictors for the disability at the first visit according to EDSS.